How Clinical Trial Data Have Shaped Amivantamab Use in Practice for EGFR-Mutated NSCLC

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, review findings from the MARIPOSA, COCOON, and PALOMA-3 trials and their impact on clinical practice regarding the use of amivantamab in EGFR-mutated non–small cell lung cancer. Spira discusses how cumulative efficacy, CNS activity, and safety data have strengthened the rationale for amivantamab plus lazertinib in the frontline setting. Raez highlights patient subsets, including those with TP53 co-mutations or CNS metastases, in whom combination strategies may offer particular clinical benefit.